Skip to content
Screener

ImmunityBio, Inc. IBRX Total Operating Expenses

Discontinued — last reported Q4 '24

Total Operating Expenses at other companies

Immunome logo
ImmunomeIMNM
$59.33M+24.7%
Artiva Biotherapeutics, Inc. logo
Artiva Biotherapeutics, Inc.ARTV
$26.89M+17.9%
CTO
Citius Oncology, Inc.CTOR
$29.95M+301%

Segments

By segment

See full
Reportable Segment$113.76M+40.6%

Other financials

Income statement

See full
Revenue$44.2M+168%
Gross profit$44.0M+167%
Operating income-$69.8M-8.3%
Net income-$632.8M-388%
EPS (diluted)-$0.62-313%

Balance sheet

See full
Cash & equivalents$205.2M+238%
Total debt$445.4M+32.2%
Total equity-$870.0M-47.1%
Total assets$646.6M+113%

Cash flow

See full
Operating cash flow-$75.4M+12.3%
CapEx$1.8M+58.4%
Free cash flow-$77.1M+11.4%

Valuation

See full
Market cap$7.68B+242%
Enterprise value$7.92B+227%
P/S54.5×+14.8×

Profitability

See full
Gross margin99.3%-0.5pp
Operating margin-185.4%-83.3pp
Net margin-606.2%-212pp
FCF margin-212%-95.8pp

Returns & leverage

See full
Return on equity-119.3%
Debt / equity0.1×
Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:OperatingExpenses.

The source filing: ImmunityBio, Inc.’s 10-K, filed March 3, 2025.

Filed
Mar 3, 2025
Fiscal year
FY2024
Accession
0001326110-25-000033
Line itemYear Ended December 31, 2024Year Ended December 31, 2023Year Ended December 31, 2022
Research and development (including amounts with related parties)190,144232,366248,149
Selling, general and administrative (including amounts with related parties)168,783129,620102,708
Impairment of intangible assets886681
Total operating costs and expenses358,927362,872351,538
Loss from operations(344,182)(362,250)(351,298)
Other income (expense), net:
Interest and investment income (loss), net7,9751,131(3,090)
Interest expense (including amounts with related parties)(114,670)(128,934)(63,515)

ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA.

FAQ

What is ImmunityBio, Inc.'s total operating expenses?
ImmunityBio, Inc. (IBRX) reported total operating expenses of $76.95M in Q4 2024.
How has ImmunityBio, Inc.'s total operating expenses changed year-over-year?
ImmunityBio, Inc.'s total operating expenses decreased by 10.0% year-over-year, from $85.53M to $76.95M.
What is the long-term trend for ImmunityBio, Inc.'s total operating expenses?
Over 3 years (2021 to 2024), ImmunityBio, Inc.'s total operating expenses has grown at a 2.7% compound annual growth rate (CAGR), from $331.21M to $358.93M.
What does total operating expenses mean?
The sum of all operating costs including COGS, SG&A, R&D, D&A, and other operating charges. Revenue minus total operating expenses equals operating income.

Ask your AI about ImmunityBio, Inc.'s total operating expenses.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude